Notable progress has been made in the past years in the classification, diagnosis and
treatment of pulmonary aspergillosis. New criteria were proposed by the Working Group of …

Allergic asthma often coexists with different pathological conditions, called multimorbidities,
that are mostly of allergic nature and share a common underlying inflammatory …

Fungal infections cause morbidity worldwide and are associated with an unacceptably high
mortality despite the availability of antifungal drugs. The incidence of mycoses is rising …

Omalizumab, a humanized mAb that binds to IgE, has been an effective therapy for patients
with severe allergic asthma; however, there are few clinical trials examining the efficacy of …

Background An unmet clinical need exists in the management of treatment-refractory allergic
bronchopulmonary aspergillosis (ABPA). Omalizumab has shown promising effects in case …

Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction (HR)
mediated by antigens to Aspergillus fumigatus. It is estimated that 2–15% of patients with …

Advances in pathophysiological understanding and the elucidation of a type 2 inflammatory
signature with interleukins 4, 5 and 13 at its center have led to the development of targeted …

Allergic bronchopulmonary aspergillosis (ABPA), a progressive fungal allergic lung disease,
is a common complication of asthma or cystic fibrosis. Although ABPA has been recognized …

Background Data are limited regarding the effectiveness of omalizumab in patients with
eosinophilic granulomatosis with polyangiitis (EGPA). Our aim was to evaluate the clinical …

abstract Biologics targeting the molecules associated with type 2 inflammation have
significantly improved the outcomes of patients with severe eosinophilic asthma and chronic …